Navigation Links
Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
Date:10/16/2007

">http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including, without limitation, statements related to the future development and potential efficacy, safety and tolerability of XL784 and the timing of the submission of XL784 data to GSK. Words such as "may," "will," "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Exelixis' current expectations. Forward-looking statements involve risks and uncertainties. Exelixis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the results of any failure of XL784 to demonstrate safety and efficacy in clinical testing, risks related to Exelixis' arrangement with SEI and Exelixis' dependence on and relationship with GSK. These and other risk factors are discussed under "Risk Factors" and elsewhere in Exelixis' Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and Exelixis' other filings with the Securities and Exchange Commission. Exelixis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Exelixis' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... , Nov. 28, 2014 The market ... to reach 7.9 billion dollars in 2014 according to ... of existing equipment and growing incidence of disease are ... Information,s X-Ray and Digital X-Ray: World Market Analysis ... Digital X-Ray: World Market Analysis can be obtained ...
(Date:11/28/2014)... 28, 2014  (Booth #7309, North Hall) — ... newest product, DCMSYS Interface WebBridge, at the 100th annual ... McCormick Place, Chicago, Illinois . ... Designed for medical facilities of any size, WebBridge ... upload any non-standard data (e.g. JPEG, TFF, PDF, TXT, ...
(Date:11/28/2014)... DONGGUAN, China , Nov. 28, 2014 ... 300328, "Eontec") announced that its biodegradable magnesium alloy bone ... an innovative medical apparatus and instrument and ... Eontec said in an interview with Science and ... Tao , that the company chairman and founder, Professor ...
Breaking Medicine Technology:Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 2Kalorama: X-Ray and Digital X-Ray Market Nears 8 Billion This Year 3Dicom Systems Announces WebBridge Interface at RSNA 2014 2Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 2Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 3Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 4
... GlySure Limited, developer of in-hospital continuous ... its $10.9 million Series C financing round. GlySure will ... approval in the United States and Europe. ... well as existing investors Amadeus Capital Partners, Chester Investments ...
... -- Global Pharm Holdings Group, Inc. (OTCBB: GPHG) ... integrated pharmaceutical company engaged in the distribution of ... herbal cultivation and sales in China through its ... today announced the appointment of Mr. Kwong Chi ...
Cached Medicine Technology:GlySure Secures $10.9 Million in Series C Financing Round 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 2Global Pharm Holdings Group, Inc. Strengthens its Board by Adding a Non-Executive Director 3
(Date:11/28/2014)... Now that the holiday season is here, ... nation's leading cash-for-junk-cars companies, is improving their cash offers ... competitive and help bring a little bit more joy ... year. , Along with purchasing expensive gifts for family ... deal with large travel expenses during the holiday season. ...
(Date:11/28/2014)... November 28, 2014 Novatus, a ... its Release v5.1 which provides customers with greater ... options. , “As we continue to evolve ... provide more functionality and improved performance in response ... CEO for Novatus. “With the enhancements that we ...
(Date:11/28/2014)... Wisconsin (PRWEB) November 28, 2014 Dr. ... plastic surgeons , announced the expansion of Quintessa Aesthetic ... center will be located at W307 N1497 Golf Road ... , According to Dr. Campbell, the new Delafield location ... procedures for patients, including: Botox, filler injectables ...
(Date:11/28/2014)... Texas (PRWEB) November 28, 2014 Dr. Paul Vitenas, ... will hold a Glitter & Glow Holiday Event for those in ... treatments offered at his practice. Glitter & Glow will take place ... Dr. Vitenas’ new location in the heart of Houston at 4208 ... of holidays and hope that you will come and celebrate the ...
(Date:11/28/2014)... Written and narrated by award winning author ... “The Happiest Man In the World: Life Lessons From ... and why Project C.U.R.E. came to be. , Raised in ... the Reverend Richard W. Jackson, Dr. Jackson exceeded his goal ... realized that he wasn’t happy. Prompted by this realization, James ...
Breaking Medicine News(10 mins):Health News:Rusty's Auto Salvage Increasing Their Cash Offers to Help Drivers Save Throughout the Busy Holiday Season 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2
... Christmas Programs and Next Year,s Services , ... in Chicago is facing a grave financial shortfall which will ... pace of donations increases this Christmas season according to its ... , "The economic downturn has attacked us ...
... of millions of people, mainly in developing countries, are ... Organization. , More than 12 million people in ... spread by the bite of infected sand flies. Nearly ... people die from the disease annually. , Researchers ...
... high-energy diet pill really save your job? It seems that ... and other retailers are seeing a significant drop in sales ... is reporting dramatically increased sales of Zantrex-3 (R), their ... (Photo: http://www.newscom.com/cgi-bin/prnh/20081216/LA52707 ) , , ...
... in mucus could fight deadly,bacteria in lungs , , TUESDAY, ... that stain the mucus in the lungs of cystic ... infections, researchers say. , The pigments may enable infectious ... communities, according to a Massachusetts Institute of Technology (MIT) ...
... that they know. Or maybe not. A new study published in Human ... human genome must pay attention to ancestry when analyzing and interpreting their ... ... someone where their ancestors were from and odds are that they know. ...
... Health (NIH) has awarded nearly $3 million to support Rush ... the health outcomes and health care cost savings for very ... , The grant will enable researchers at Rush to ... 600 very low birth weight infants born to racially and ...
Cached Medicine News:Health News:Salvation Army Services Threatened by Pace of Donations 2Health News:UIC researchers hunting drugs for devastating parasitic disease 2Health News:Sales of Energy-Boosting Diet Pills Skyrocket as the Economy Falters 2Health News:Scientists Spot Key to Cystic Fibrosis Infections 2Health News:Genome-wide Association Studies Must Account for Ancestry 2Health News:Genome-wide Association Studies Must Account for Ancestry 3Health News:Study examines how breastfeeding impacts cost of care for very low birth weight infants 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: